SG11202003278RA - Anti-msln antibody and pharmaceutical composition for cancer treatment comprising same - Google Patents

Anti-msln antibody and pharmaceutical composition for cancer treatment comprising same

Info

Publication number
SG11202003278RA
SG11202003278RA SG11202003278RA SG11202003278RA SG11202003278RA SG 11202003278R A SG11202003278R A SG 11202003278RA SG 11202003278R A SG11202003278R A SG 11202003278RA SG 11202003278R A SG11202003278R A SG 11202003278RA SG 11202003278R A SG11202003278R A SG 11202003278RA
Authority
SG
Singapore
Prior art keywords
pharmaceutical composition
same
cancer treatment
msln antibody
msln
Prior art date
Application number
SG11202003278RA
Inventor
Ki Su Kim
Jun Hong Jeong
Dong Sik Kim
Yang Mi Lim
Yong Yea Park
Hyung Kwon Lim
Jong Wha Won
Original Assignee
Green Cross Corp
Mogam Inst Biomedical Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Green Cross Corp, Mogam Inst Biomedical Res filed Critical Green Cross Corp
Publication of SG11202003278RA publication Critical patent/SG11202003278RA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
SG11202003278RA 2017-10-20 2018-10-22 Anti-msln antibody and pharmaceutical composition for cancer treatment comprising same SG11202003278RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020170136565A KR101966362B1 (en) 2017-10-20 2017-10-20 Antibody against msln and pharmaceutical composition for treating cancer comprising the same
PCT/KR2018/012493 WO2019078698A2 (en) 2017-10-20 2018-10-22 Anti-msln antibody and pharmaceutical composition for cancer treatment comprising same

Publications (1)

Publication Number Publication Date
SG11202003278RA true SG11202003278RA (en) 2020-05-28

Family

ID=66103738

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202003278RA SG11202003278RA (en) 2017-10-20 2018-10-22 Anti-msln antibody and pharmaceutical composition for cancer treatment comprising same

Country Status (14)

Country Link
US (1) US11401343B2 (en)
EP (1) EP3699199A4 (en)
JP (1) JP6978598B2 (en)
KR (1) KR101966362B1 (en)
CN (1) CN111247173B (en)
AU (1) AU2018351417B2 (en)
BR (1) BR112020007739A2 (en)
CA (1) CA3077009C (en)
EA (1) EA202090945A1 (en)
IL (1) IL274008A (en)
MX (1) MX2020003943A (en)
MY (1) MY194272A (en)
SG (1) SG11202003278RA (en)
WO (1) WO2019078698A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3134680C (en) * 2019-03-29 2024-02-06 Green Cross Corporation Fusion protein comprising anti-mesothelin antibody, anti-cd3 antibody or anti-egfr antibody, bispecific or trispecific antibody comprising same, and uses thereof
CN117396515A (en) * 2021-05-19 2024-01-12 南京再明医药有限公司 anti-MSLN antibodies and uses thereof
WO2023131276A1 (en) * 2022-01-06 2023-07-13 原启生物科技(上海)有限责任公司 Antigen binding protein targeting msln and use thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
ES2526355T3 (en) 2007-10-01 2015-01-09 Bristol-Myers Squibb Company Human antibodies that adhere to mesothelin, and uses thereof
UY32560A (en) 2009-04-29 2010-11-30 Bayer Schering Pharma Ag IMMUNOCONJUGADOS OF ANTIMESOTELINA AND USES OF THE SAME
KR101108642B1 (en) * 2009-09-29 2012-02-09 주식회사 녹십자 Antibodies specifically binding to the epidermal growth factor receptor
US20140004121A1 (en) * 2012-06-27 2014-01-02 Amgen Inc. Anti-mesothelin binding proteins
JP6307085B2 (en) * 2012-09-27 2018-04-04 ザ・ユナイテッド・ステイツ・オブ・アメリカ・アズ・リプリゼンテッド・バイ・ザ・セクレタリー・デパートメント・オブ・ヘルス・アンド・ヒューマン・サービシーズThe United States of America,as represented by the Secretary,Department of Health and Human Services Mesothelin antibodies and methods for eliciting potent anti-tumor activity
EP3339326A4 (en) 2015-08-21 2019-01-09 Carsgen Therapeutics Limited Fully human anti-mesothelin antibodies and immune effector cells targeting mesothelin
KR101782487B1 (en) 2015-09-24 2017-09-27 재단법인 목암생명과학연구소 Novel Antibody Binding to Mesothelin(MSLN), and Composition Comprising the Same

Also Published As

Publication number Publication date
MY194272A (en) 2022-11-25
CA3077009A1 (en) 2019-04-25
AU2018351417B2 (en) 2021-12-23
US20200262928A1 (en) 2020-08-20
KR101966362B1 (en) 2019-04-05
AU2018351417A1 (en) 2020-05-28
CN111247173B (en) 2024-03-29
CN111247173A (en) 2020-06-05
US11401343B2 (en) 2022-08-02
CA3077009C (en) 2023-05-16
MX2020003943A (en) 2020-08-13
EA202090945A1 (en) 2020-07-14
EP3699199A4 (en) 2021-06-30
WO2019078698A2 (en) 2019-04-25
WO2019078698A3 (en) 2019-07-04
BR112020007739A2 (en) 2020-10-20
IL274008A (en) 2020-05-31
JP2021507678A (en) 2021-02-25
EP3699199A2 (en) 2020-08-26
JP6978598B2 (en) 2021-12-08

Similar Documents

Publication Publication Date Title
PT3616720T (en) Pharmaceutical composition for cancer treatment
EP3533466A4 (en) Pharmaceutical composition for cancer treatment and/or prevention
IL260474B (en) Cadherin-17 specific antibodies and cytotoxic cells for cancer treatment
IL266486A (en) Pharmaceutical compositions and methods for the treatment of cancer
IL268416A (en) Pharmaceutical combinations for treating cancer
IL275525A (en) Pharmaceutical composition for the treatment of cancer
IL274008A (en) Anti-msln antibody and pharmaceutical composition comprising same for cancer treatment
IL280587B (en) Flurocytidine derivatives and its composition for the treatment of cancer
EP3708173C0 (en) Pharmaceutical composition comprising mirna-3140 for use in treating cancer
ZA201802618B (en) Anti-cd43 antibody and use thereof for cancer treatment
IL274007A (en) Anti-cd3 antibody and pharmaceutical composition for cancer treatment comprising same
HUE047272T2 (en) Pharmaceutical composition for treating and/or preventing cancer
IL272147A (en) Methods and compositions for the treatment of cancer
EP3563856A4 (en) Pharmaceutical composition for treating cancer and use thereof
EP3406626A4 (en) Peptide for cancer treatment and pharmaceutical composition containing same
EP3372233A4 (en) Pharmaceutical composition for treating and/or preventing cancer
IL249860A0 (en) Pharmaceutical compositions, methods for their preparation and their use in the treatment of cancer
PT3236961T (en) Pharmaceutical composition for preventing or treating cancer and method using thereof
GB201718927D0 (en) Pharmaceutical composition suitable for intestinal cancer treatment and/or prevention
EP3552632A4 (en) Medicinal composition for treating and preventing chronic disease
EP3498284A4 (en) Pharmaceutical composition for treating and/or preventing cancer
EP3441465A4 (en) Cancer treatment pharmaceutical composition using anti-mct5 antibody
IL274866A (en) Compositions and methods for cancer therapy
EP3437655A4 (en) Pharmaceutical composition for treating and/or preventing cancer
EP3437656A4 (en) Pharmaceutical composition for treating and/or preventing cancer